替罗非班治疗不稳定性心绞痛51例

Efficacy and Safety of Tirofiban in the Treatment of Unstable Angina

目的观察替罗非班治疗不稳定性心绞痛的临床疗效和安全性。方法符合不稳定性心绞痛诊断标准的患者106例,随机分为替罗非班组和对照组,两组均给予阿司匹林、氯吡格雷和低分子肝素,替罗非班组加用替罗非班。观察两组患者30天后的主要心血管事件、左室射血分数及出血事件。结果替罗非班组的主要心血管事件少于常规治疗组,替罗非班组的心功能改善优于对照组,两组的出血事件发生率比较,差异无显著性。结论替罗非班可减少不稳定性心绞痛患者的心血管事件,改善心功能,不增加出血事件。

Objective To evaluate the efficacy and safety of tirofiban in the treatment of unstable angina.Method A total of 106 patients were randomly assigned to tirofiban group and control group,all patients were administrated with aspirin,clopidogrel and low molecular weight heparin,and tirofiban group were received intravenous tirofiban additionally.Major adverse cardiovascular event（MACE）,left ventricular ejection fraction（LVEF） and bleeding complication were observed after 30 days. Result The frequency of MACE was lower in tirofiban group as compared with that of control group.Higher LVEF was observed in the tirofiban group.The frequency of bleeding complication was not different in the two groups.Conclusions Treatment with tirofiban will get lower MACE and higher LVEF in unstable angina patients.Treatment with tirofiban is safe.